KRAS and non-small cell lung carcinoma: For instance, sotorasib has been shown to improve clinical and patient-reported outcomes compared with docetaxel in patients with KRAS G12C-mutated NSCLC, as demonstrated in the CodeBreaK 200 trial [10,11].